-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $5.5

Benzinga·05/06/2026 13:40:01
Listen to the news
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6 to $5.5.